Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS (ALNEV)

367
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/27/2015 03/02/2015 03/03/2015 03/04/2015 03/05/2015 Date
1.11(c) 1.1(c) 1.12(c) 1.16(c) 1.15 Last
272 210 129 633 163 510 1 596 076 203 774 Volume
0.00% -0.90% +1.82% +3.57% -0.86% Change
More quotes
Company
Neovacs SA is a biotechnology company.It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer.It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid.The Tumor Necrosis... 
Sector
Biotechnology & Medical Research
Calendar
03/10 | 10:30amPresentation
More about the company
Surperformance© ratings of NEOVACS
Trading Rating : Investor Rating :
More Ratings
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 0,03 M
EBIT 2014 -8,20 M
Net income 2014 -7,21 M
Debt 2014 2,79 M
Yield 2014 -
Sales 2015 5,03 M
EBIT 2015 -5,58 M
Net income 2015 -6,46 M
Debt 2015 7,39 M
Yield 2015 -
PER 2014 -
PER 2015 1,21
EV / Sales 2014 1 179x
EV / Sales 2015 6,78x
Capitalization 26,7 M
More Financials
Latest news on NEOVACS
03/04 NEOVACS : Scientific Advisory Board endorses company’s updated IFNa-Kinoid..
03/04 NEOVACS : CORRECTION: NEOVACS :NEOVACS SCIENTIFIC ADVISORY BOARD ENDORSES COMPAN..
03/04 NEOVACS : Scientific Advisory Board Endorses Company's Updated IFNa-Kinoid Devel..
03/04 NEOVACS : SCIENTIFIC ADVISORY BOARD ENDORSES COMPANY'S UPDATED IFNalpha-KINOID D..
03/04 NEOVACS : SCIENTIFIC ADVISORY BOARD ENDORSES COMPANY'S UPDATED IFNα-KINOID..
02/27 NEOVACS : Financial Results For 2014
02/27 NEOVACS : FINANCIAL RESULTS FOR 2014 (DGAP News)
02/27 NEOVACS : Financial results for 2014
More news
Sector news Biotechnology & Medical Research - NEC
06:16aDJMARKET SNAPSHOT : U.S. Stocks: Investors Cautious Ahead Of ECB, Crop Of U.S. Dat..
03:30a AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
03:30a AbbVie boosts cancer drug pipeline with $21 billion Pharmacyclics deal
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF